Home » Stocks » REPL

Replimune Group, Inc. (REPL)

Stock Price: $39.41 USD -5.63 (-12.50%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $41.25 +1.84 (4.67%) Jan 27, 4:00 AM
Market Cap 1.81B
Revenue (ttm) n/a
Net Income (ttm) -69.57M
Shares Out 44.02M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $39.41
Previous Close $45.04
Change ($) -5.63
Change (%) -12.50%
Day's Open 45.41
Day's Range 38.65 - 46.64
Day's Volume 745,032
52-Week Range 8.90 - 52.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash.

The Motley Fool - 2 months ago

One has a better chance to keep climbing than the other does.

Other stocks mentioned: SURF
GlobeNewsWire - 2 months ago

RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development

The Motley Fool - 2 months ago

Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.

Other stocks mentioned: SRRK
GlobeNewsWire - 3 months ago

BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today a...

GlobeNewsWire - 3 months ago

BOSTON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today a...

GlobeNewsWire - 3 months ago

WOBURN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, ...

GlobeNewsWire - 3 months ago

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, ...

The Motley Fool - 3 months ago

The company plans to present encouraging early-stage clinical data at a major conference next month.

GlobeNewsWire - 3 months ago

I nitial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors

GlobeNewsWire - 3 months ago

WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, t...

GlobeNewsWire - 5 months ago

Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 ref...

GlobeNewsWire - 5 months ago

WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...

GlobeNewsWire - 6 months ago

WOBURN, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform...

GlobeNewsWire - 7 months ago

WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...

Zacks Investment Research - 7 months ago

Replimune (REPL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

WOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulyt...

GlobeNewsWire - 9 months ago

WOBURN, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform...

GlobeNewsWire - 1 year ago

RP1: Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo®) in cutaneous squamous cell carcinoma (CSCC) underway

GlobeNewsWire - 1 year ago

WOBURN, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...

GlobeNewsWire - 1 year ago

WOBURN, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,...

GuruFocus - 1 year ago

Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?

Other stocks mentioned: ET, KDMN
GlobeNewsWire - 1 year ago

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...

GlobeNewsWire - 1 year ago

BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...

GlobeNewsWire - 1 year ago

Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types

GlobeNewsWire - 1 year ago

Replimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4 antibody-like protein Replimune’s second product candidate to enter the clinic is an Imm...

GlobeNewsWire - 1 year ago

Abstract highlights initial data from Phase 1 part of Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo® (nivolumab) Abstract highlights initial data from Phase 1 part of Ph...

Seeking Alpha - 1 year ago

Shares have lost 4% of their value since my April article.

Seeking Alpha - 1 year ago

Share price performance is relatively flat since July 2018 IPO.

Benzinga - 1 year ago

Replimune Group Inc (NASDAQ: REPL)'s lead asset is expected to quickly pass through development and clear the FDA hurdle, according to Wedbush. 

About REPL

Replimune Group, a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is... [Read more...]

Industry
Biotechnology
IPO Date
Jul 20, 2018
CEO
philip Astley-Sparke
Employees
122
Stock Exchange
NASDAQ
Ticker Symbol
REPL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for REPL stock is "Buy." The 12-month stock price forecast is 55.70, which is an increase of 41.33% from the latest price.

Price Target
$55.70
(41.33% upside)
Analyst Consensus: Buy